Sanofi and Regeneron Strike $7 Billion Deal for New Treatments
French drugmaker Sanofi has entered into a $7 billion agreement with Regeneron to develop new treatments. This strategic move aims to replenish Sanofi's drug pipeline as a key existing drug approaches patent expiry. The company's new CEO possesses the financial capacity to pursue further acquisitions.